Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04609566
Title Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Seagen Inc.
Indications

lung non-small cell carcinoma

skin melanoma

Therapies

Brentuximab vedotin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST